Contemporary insights into the pathogenesis and treatment of chronic myeloproliferative neoplasms.

about

Proteomic analysis of JAK2V617F-induced changes identifies potential new combinatorial therapeutic approaches.

P2860

Q47102210-96798440-2422-4484-8AA8-F1C606AFFB52

P2860

Contemporary insights into the pathogenesis and treatment of chronic myeloproliferative neoplasms.

Item

http://www.wikidata.org/entity/Q38848273

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Contemporary insights into the ...... myeloproliferative neoplasms.

@en

type

Item

label

Contemporary insights into the ...... myeloproliferative neoplasms.

@en

prefLabel

Contemporary insights into the ...... myeloproliferative neoplasms.

@en

P1476

Contemporary insights into the ...... myeloproliferative neoplasms.

@en

P2093

Omar Abdel-Wahab

http://www.w3.org/2001/XMLSchema#string

Raajit Rampal

http://www.w3.org/2001/XMLSchema#string

Richard A Van Etten

http://www.w3.org/2001/XMLSchema#string

Ross Levine

http://www.w3.org/2001/XMLSchema#string

Ruben Mesa

http://www.w3.org/2001/XMLSchema#string

Rüdiger Hehlmann

http://www.w3.org/2001/XMLSchema#string

Tariq I Mughal

http://www.w3.org/2001/XMLSchema#string

Tiziano Barbui

http://www.w3.org/2001/XMLSchema#string

P2860

Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2

Chronic myeloid leukemia: reminiscences and dreams

Asyn-anticonformational difference allows SRSF2 to recognize guanines and cytosines equally well

Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimizati

Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: Data from the FDA Adverse Event Reporting System.

Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV.

P304

1517-1526

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/10428194.2016.1185783

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Giuseppe Saglio

Steffen Koschmieder

P577

2016-05-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27240645

http://www.w3.org/2001/XMLSchema#string

P932

6077976

http://www.w3.org/2001/XMLSchema#string

Contemporary insights into the pathogenesis and treatment of chronic myeloproliferative neoplasms.

about

P2860

P2860

Contemporary insights into the pathogenesis and treatment of chronic myeloproliferative neoplasms.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932